185 related articles for article (PubMed ID: 38602846)
1. Discovery of the First-in-Class G9a/GLP PROTAC Degrader.
Velez J; Han Y; Yim H; Yang P; Deng Z; Park KS; Kabir M; Kaniskan HÜ; Xiong Y; Jin J
J Med Chem; 2024 Apr; 67(8):6397-6409. PubMed ID: 38602846
[TBL] [Abstract][Full Text] [Related]
2. Discovery of the First-in-class G9a/GLP PROTAC Degrader.
Velez J; Han Y; Yim H; Yang P; Deng Z; Park KS; Kabir M; Kaniskan HÜ; Xiong Y; Jin J
bioRxiv; 2024 Feb; ():. PubMed ID: 38464025
[TBL] [Abstract][Full Text] [Related]
3. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
Liu F; Barsyte-Lovejoy D; Li F; Xiong Y; Korboukh V; Huang XP; Allali-Hassani A; Janzen WP; Roth BL; Frye SV; Arrowsmith CH; Brown PJ; Vedadi M; Jin J
J Med Chem; 2013 Nov; 56(21):8931-42. PubMed ID: 24102134
[TBL] [Abstract][Full Text] [Related]
4. Discovery of the First-in-Class G9a/GLP Covalent Inhibitors.
Park KS; Xiong Y; Yim H; Velez J; Babault N; Kumar P; Liu J; Jin J
J Med Chem; 2022 Aug; 65(15):10506-10522. PubMed ID: 35763668
[TBL] [Abstract][Full Text] [Related]
5. Targeting H3K9 methyltransferase G9a and its related molecule GLP as a potential therapeutic strategy for cancer.
Rahman Z; Bazaz MR; Devabattula G; Khan MA; Godugu C
J Biochem Mol Toxicol; 2021 Mar; 35(3):e22674. PubMed ID: 33283949
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase.
Xiong Y; Li F; Babault N; Dong A; Zeng H; Wu H; Chen X; Arrowsmith CH; Brown PJ; Liu J; Vedadi M; Jin J
J Med Chem; 2017 Mar; 60(5):1876-1891. PubMed ID: 28135087
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines.
Katayama K; Ishii K; Tsuda E; Yotsumoto K; Hiramoto K; Suzuki M; Yasumatsu I; Igarashi W; Torihata M; Ishiyama T; Katagiri T
Bioorg Med Chem Lett; 2020 Oct; 30(20):127475. PubMed ID: 32781218
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells.
Cao YP; Sun JY; Li MQ; Dong Y; Zhang YH; Yan J; Huang RM; Yan X
Acta Pharmacol Sin; 2019 Aug; 40(8):1076-1084. PubMed ID: 30765842
[TBL] [Abstract][Full Text] [Related]
9. G9a - An Appealing Antineoplastic Target.
Chen WL; Sun HP; Li DD; Wang ZH; You QD; Guo XK
Curr Cancer Drug Targets; 2017; 17(6):555-568. PubMed ID: 27174055
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
Lenstra DC; Al Temimi AHK; Mecinović J
Bioorg Med Chem Lett; 2018 Apr; 28(7):1234-1238. PubMed ID: 29519735
[TBL] [Abstract][Full Text] [Related]
11. Heterodimerization of H3K9 histone methyltransferases G9a and GLP activates methyl reading and writing capabilities.
Sanchez NA; Kallweit LM; Trnka MJ; Clemmer CL; Al-Sady B
J Biol Chem; 2021 Nov; 297(5):101276. PubMed ID: 34619147
[TBL] [Abstract][Full Text] [Related]
12. Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.
Chen WL; Wang ZH; Feng TT; Li DD; Wang CH; Xu XL; Zhang XJ; You QD; Guo XK
Bioorg Med Chem; 2016 Nov; 24(22):6102-6108. PubMed ID: 27720557
[TBL] [Abstract][Full Text] [Related]
13. Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents.
Cao H; Li L; Yang D; Zeng L; Yewei X; Yu B; Liao G; Chen J
Eur J Med Chem; 2019 Oct; 179():537-546. PubMed ID: 31276898
[TBL] [Abstract][Full Text] [Related]
14. Discovery of LLC0424 as a Potent and Selective
Liu L; Parolia A; Liu Y; Hou C; He T; Qiao Y; Eyunni S; Luo J; Li C; Wang Y; Zhou F; Huang W; Ren X; Wang Z; Chinnaiyan AM; Ding K
J Med Chem; 2024 May; 67(9):6938-6951. PubMed ID: 38687638
[TBL] [Abstract][Full Text] [Related]
15. Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells.
Link PA; Gangisetty O; James SR; Woloszynska-Read A; Tachibana M; Shinkai Y; Karpf AR
Mol Cancer Res; 2009 Jun; 7(6):851-62. PubMed ID: 19531572
[TBL] [Abstract][Full Text] [Related]
16. GLP overexpression is associated with poor prognosis in Chronic Lymphocytic Leukemia and its inhibition induces leukemic cell death.
Alves-Silva JC; de Carvalho JL; Rabello DA; Serejo TRT; Rego EM; Neves FAR; Lucena-Araujo AR; Pittella-Silva F; Saldanha-Araujo F
Invest New Drugs; 2018 Oct; 36(5):955-960. PubMed ID: 29855824
[TBL] [Abstract][Full Text] [Related]
17. The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.
Pappano WN; Guo J; He Y; Ferguson D; Jagadeeswaran S; Osterling DJ; Gao W; Spence JK; Pliushchev M; Sweis RF; Buchanan FG; Michaelides MR; Shoemaker AR; Tse C; Chiang GG
PLoS One; 2015; 10(7):e0131716. PubMed ID: 26147105
[TBL] [Abstract][Full Text] [Related]
18. The zinc finger proteins ZNF644 and WIZ regulate the G9a/GLP complex for gene repression.
Bian C; Chen Q; Yu X
Elife; 2015 Mar; 4():. PubMed ID: 25789554
[TBL] [Abstract][Full Text] [Related]
19. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines.
Liu F; Chen X; Allali-Hassani A; Quinn AM; Wigle TJ; Wasney GA; Dong A; Senisterra G; Chau I; Siarheyeva A; Norris JL; Kireev DB; Jadhav A; Herold JM; Janzen WP; Arrowsmith CH; Frye SV; Brown PJ; Simeonov A; Vedadi M; Jin J
J Med Chem; 2010 Aug; 53(15):5844-57. PubMed ID: 20614940
[TBL] [Abstract][Full Text] [Related]
20. Insights for the design of protein lysine methyltransferase G9a inhibitors.
Charles MRC; Dhayalan A; Hsieh HP; Coumar MS
Future Med Chem; 2019 May; 11(9):993-1014. PubMed ID: 31141392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
